Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.

Dr Philip J. Mease shares his insights on the use of ultrasound in psoriatic arthritis diagnosis, particularly in uncovering ...

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

In three different trials, the sex differences were mapped between women and men with psoriatic arthritis in their manifestations and outcomes.

Another potential drawback is the exclusion of patients with disease initiation after the age of 45 years, which is not uncommon in peripheral SpA. It also remains unclear what degree of spinal ...